Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study

Fabien Zoulim, Giampiero Carosi, Susan Greenbloom, Wlodzimierz Mazur, Tuan Nguyen, Lennox J Jeffers, Maurizia Brunetto, Song Yu, Cyril Llamoso

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background & Aims Serum hepatitis B surface antigen (HBsAg) levels may predict treatment response in chronic hepatitis B (CHB). We examined the association between changes in HBsAg levels and response to treatment in the BE-LOW study.

Methods In this open-label, multicentre study, 379 nucleos(t)ide-naïve patients with hepatitis B e antigen (HBeAg)-positive or -negative CHB were randomized and treated with daily entecavir 0.5 mg alone (n = 182) or combined with tenofovir 300 mg (n = 197) for 100 weeks. HBsAg levels were quantified (Abbott Architect assay) at baseline and at Weeks 12, 48, and 96.

Results Mean baseline HBsAg levels were comparable across subgroups by baseline alanine aminotransferase (ALT), genotype, age, and treatment type, but were higher in HBeAg-positive than in HBeAg-negative patients. Mean HBsAg changes from baseline at Weeks 12, 48, and 96 were more pronounced in HBeAg-positive than in HBeAg-negative patients, in patients with genotype A than in those with genotypes C or D, and in patients with elevated baseline ALT, but were similar between treatment groups and between patients of different age categories. Mean HBsAg changes over 96 weeks were also comparable in patients with or without HBV DNA <50 IU/ml at Week 96, but among patients that were HBeAg-positive at baseline, changes were greater for those with Week 96 HBeAg loss than for those without.

Conclusions In this population of HBeAg-positive and HBeAg-negative, nucleos(t)ide-naïve patients, a greater HBsAg decline through 96 treatment weeks was observed in HBeAg-positive patients, especially in those who achieved subsequent HBeAg loss.

Original languageEnglish
Pages (from-to)56-63
Number of pages8
JournalJournal of Hepatology
Volume62
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Tenofovir
Hepatitis B e Antigens
Chronic Hepatitis B
Hepatitis B Surface Antigens
Genotype
Alanine Transaminase
entecavir
Therapeutics

ASJC Scopus subject areas

  • Hepatology

Cite this

Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. / Zoulim, Fabien; Carosi, Giampiero; Greenbloom, Susan; Mazur, Wlodzimierz; Nguyen, Tuan; Jeffers, Lennox J; Brunetto, Maurizia; Yu, Song; Llamoso, Cyril.

In: Journal of Hepatology, Vol. 62, No. 1, 01.01.2014, p. 56-63.

Research output: Contribution to journalArticle

Zoulim, F, Carosi, G, Greenbloom, S, Mazur, W, Nguyen, T, Jeffers, LJ, Brunetto, M, Yu, S & Llamoso, C 2014, 'Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study', Journal of Hepatology, vol. 62, no. 1, pp. 56-63. https://doi.org/10.1016/j.jhep.2014.08.031
Zoulim, Fabien ; Carosi, Giampiero ; Greenbloom, Susan ; Mazur, Wlodzimierz ; Nguyen, Tuan ; Jeffers, Lennox J ; Brunetto, Maurizia ; Yu, Song ; Llamoso, Cyril. / Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. In: Journal of Hepatology. 2014 ; Vol. 62, No. 1. pp. 56-63.
@article{22244b6f872140b48d32ad4cbc54774f,
title = "Quantification of HBsAg in nucleos(t)ide-na{\"i}ve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study",
abstract = "Background & Aims Serum hepatitis B surface antigen (HBsAg) levels may predict treatment response in chronic hepatitis B (CHB). We examined the association between changes in HBsAg levels and response to treatment in the BE-LOW study.Methods In this open-label, multicentre study, 379 nucleos(t)ide-na{\"i}ve patients with hepatitis B e antigen (HBeAg)-positive or -negative CHB were randomized and treated with daily entecavir 0.5 mg alone (n = 182) or combined with tenofovir 300 mg (n = 197) for 100 weeks. HBsAg levels were quantified (Abbott Architect assay) at baseline and at Weeks 12, 48, and 96.Results Mean baseline HBsAg levels were comparable across subgroups by baseline alanine aminotransferase (ALT), genotype, age, and treatment type, but were higher in HBeAg-positive than in HBeAg-negative patients. Mean HBsAg changes from baseline at Weeks 12, 48, and 96 were more pronounced in HBeAg-positive than in HBeAg-negative patients, in patients with genotype A than in those with genotypes C or D, and in patients with elevated baseline ALT, but were similar between treatment groups and between patients of different age categories. Mean HBsAg changes over 96 weeks were also comparable in patients with or without HBV DNA <50 IU/ml at Week 96, but among patients that were HBeAg-positive at baseline, changes were greater for those with Week 96 HBeAg loss than for those without.Conclusions In this population of HBeAg-positive and HBeAg-negative, nucleos(t)ide-na{\"i}ve patients, a greater HBsAg decline through 96 treatment weeks was observed in HBeAg-positive patients, especially in those who achieved subsequent HBeAg loss.",
author = "Fabien Zoulim and Giampiero Carosi and Susan Greenbloom and Wlodzimierz Mazur and Tuan Nguyen and Jeffers, {Lennox J} and Maurizia Brunetto and Song Yu and Cyril Llamoso",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.jhep.2014.08.031",
language = "English",
volume = "62",
pages = "56--63",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study

AU - Zoulim, Fabien

AU - Carosi, Giampiero

AU - Greenbloom, Susan

AU - Mazur, Wlodzimierz

AU - Nguyen, Tuan

AU - Jeffers, Lennox J

AU - Brunetto, Maurizia

AU - Yu, Song

AU - Llamoso, Cyril

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background & Aims Serum hepatitis B surface antigen (HBsAg) levels may predict treatment response in chronic hepatitis B (CHB). We examined the association between changes in HBsAg levels and response to treatment in the BE-LOW study.Methods In this open-label, multicentre study, 379 nucleos(t)ide-naïve patients with hepatitis B e antigen (HBeAg)-positive or -negative CHB were randomized and treated with daily entecavir 0.5 mg alone (n = 182) or combined with tenofovir 300 mg (n = 197) for 100 weeks. HBsAg levels were quantified (Abbott Architect assay) at baseline and at Weeks 12, 48, and 96.Results Mean baseline HBsAg levels were comparable across subgroups by baseline alanine aminotransferase (ALT), genotype, age, and treatment type, but were higher in HBeAg-positive than in HBeAg-negative patients. Mean HBsAg changes from baseline at Weeks 12, 48, and 96 were more pronounced in HBeAg-positive than in HBeAg-negative patients, in patients with genotype A than in those with genotypes C or D, and in patients with elevated baseline ALT, but were similar between treatment groups and between patients of different age categories. Mean HBsAg changes over 96 weeks were also comparable in patients with or without HBV DNA <50 IU/ml at Week 96, but among patients that were HBeAg-positive at baseline, changes were greater for those with Week 96 HBeAg loss than for those without.Conclusions In this population of HBeAg-positive and HBeAg-negative, nucleos(t)ide-naïve patients, a greater HBsAg decline through 96 treatment weeks was observed in HBeAg-positive patients, especially in those who achieved subsequent HBeAg loss.

AB - Background & Aims Serum hepatitis B surface antigen (HBsAg) levels may predict treatment response in chronic hepatitis B (CHB). We examined the association between changes in HBsAg levels and response to treatment in the BE-LOW study.Methods In this open-label, multicentre study, 379 nucleos(t)ide-naïve patients with hepatitis B e antigen (HBeAg)-positive or -negative CHB were randomized and treated with daily entecavir 0.5 mg alone (n = 182) or combined with tenofovir 300 mg (n = 197) for 100 weeks. HBsAg levels were quantified (Abbott Architect assay) at baseline and at Weeks 12, 48, and 96.Results Mean baseline HBsAg levels were comparable across subgroups by baseline alanine aminotransferase (ALT), genotype, age, and treatment type, but were higher in HBeAg-positive than in HBeAg-negative patients. Mean HBsAg changes from baseline at Weeks 12, 48, and 96 were more pronounced in HBeAg-positive than in HBeAg-negative patients, in patients with genotype A than in those with genotypes C or D, and in patients with elevated baseline ALT, but were similar between treatment groups and between patients of different age categories. Mean HBsAg changes over 96 weeks were also comparable in patients with or without HBV DNA <50 IU/ml at Week 96, but among patients that were HBeAg-positive at baseline, changes were greater for those with Week 96 HBeAg loss than for those without.Conclusions In this population of HBeAg-positive and HBeAg-negative, nucleos(t)ide-naïve patients, a greater HBsAg decline through 96 treatment weeks was observed in HBeAg-positive patients, especially in those who achieved subsequent HBeAg loss.

UR - http://www.scopus.com/inward/record.url?scp=84918514643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918514643&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2014.08.031

DO - 10.1016/j.jhep.2014.08.031

M3 - Article

C2 - 25176615

AN - SCOPUS:84918514643

VL - 62

SP - 56

EP - 63

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 1

ER -